Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Oncolytics Biotech Inc.
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Risks Related to the Companies Operations === * As a clinical stage pharmaceutical company, the prospects of Oncolytics Biotech is regarded as speculative, it is impossible to predict whether new therapeutics will ultimately prove to be safe and effective in humans or whether necessary and sufficient data can be developed through the clinical trial process to support a successful product application and approval * Their current product in development, Pelareorep, is in it's R&D stage for human application, the riskiest stage for a company in the biotechnology industry * If they are unable to establish that Pelareorep is a safe, effective treatment for cancer, they may be required to abandon further development of the product and develop a new business strategy
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)